MSB has the internal capability to prepare the BLA, however, with more than 100,000 patients/year entering care (US alone), the company has been transparent on its intention to partner this asset.There are numerous factors to consider for a partner including:The confirmatory study will be a long, expensive project – costing many tens of US$m;MSB has limited resources and many other clinical programs to conduct, not the least of which includes capital commitments for clinical trials to expand the label on Ryoncil and the ongoing commitment for the Rexlemostrocel in the CLBP trial2;We consider partnering the asset post receiving accelerated approval is a reasonable outcome and would entitle MSB to a handsome up front payment and a mid teens royalty stream plus development and commercialisation milestones. Under such an arrangement the development partner would fund the confirmatory study. This is just one of multiple potential outcomes.
Aloha.
MSB Price at posting:
$1.79 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)